Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (193)	3/7/2002 3:47:49 AM
From: nigel bates	Read Replies (1) of 469

OXFORD, UK, March 7 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) announces that Michael Kranda has informed the Board of Directors of his intention to step down by the end of this year for personal family reasons. OGS Chairman G. Kirk Raab announced that the Company has initiated a search to replace Michael Kranda as Chief Executive Officer. Kirk Raab said: ``Over the last 6 years Michael has helped us build a uniquely wealthy company in terms of proprietary technology, pipeline, partnerships and financial strength. We will miss Michael's unique contribution as CEO but he will stay on through the transition period and I am confident that OGS' programmes and progress will continue unabated. We have a highly experienced management team, a strong commercial organization building under Don DeGoyler's leadership and a Board of Directors made up of career drug discovery and development professionals.'' Michael Kranda said: ``I have truly enjoyed helping to build OGS into the Proteomics pioneer and drug discovery and development company it is today. I am proud of how far we have come in these 6 years and I have every expectation that OGS will continue on its path to creating substantial share holder value in the future. I am committed to continue day-to-day leadership and make this a seamless transition.'' For further information please contact: Oxford GlycoSciences Plc Michael Kranda, Chief Executive Officer Dr Stephen Parker, Chief Financial Officer Tel: +44 (0) 1235 208000 WorldWide Web: www.ogs.com UK: Financial Dynamics David Yates/Sarah Mehanna Tel: +44 (0) 20 7831 3113 +44 (0) 20 7269 7236 USA: Feinstein Kean Michelle Linn/Michael Lawson Tel: +1 (617) 761 6765 +1 (617) 577 8110

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next